It will come down to whether the health industry sees it as a material improvement on what is currently available.
If it is highly regarded and well marketed, they should not have a problem from here.
If they cannot get a health industry partner = problem, maybe all over.
Until they get a well heeled and connected partner its a spec.
Seimens have been touted as a potential partner.
A partner will want a fair slice of the pie, i.e., the IBX quoted $US1500 per test or a big slice of equity.
It will come down to whether the health industry sees it as a...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
